Alnylam Pharmaceuticals
NEWS
This morning, Alnylam announced vutrisiran met primary and all secondary endpoints. Here’s everything you need to know about the drug and its purpose.
Diversity and Inclusion (D&I) have been at the forefront of the national conversation during this momentous year, so BioSpace felt it imperative to reach out to employees in the life sciences industry on this subject in our wide-ranging Fall 2020 Diversity and Inclusion Survey.
Despite the constant need for social distancing, mask-wearing, and the isolation and economic uncertainty that resulted from the outbreak, there is still much to be thankful for when families gather around a virtual table to break bread and carve the turkey this year.
The end of November and beginning of December is marked by several PDUFA dates at the U.S. Food and Drug Administration (FDA). Here’s a look.
The U.S. FDA approved Alnylam Pharmaceuticals’ Oxlumo (lumasiran) for primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in children and adults.
Two Phase III studies of lumasiran showed a significant reduction in urinary oxalate excretion in patients of all ages with PH1. Know more about it here.
Alnilam – the bright center star in the middle of Orion’s belt – has navigated its namesake Alnylam to positive results in their ILLUMINATE-B Phase III clinical trial evaluating RNAi therapeutic, lumasiran, in young children with Primary hyperoxaluria Type 1 (PH1).
It was a fairly busy week with clinical trial updates and announcements. Here’s a look.
The results of Lumasiran were presented at the European Renal Association-European Dialysis and Transplant Association International Congress.
JOBS
IN THE PRESS